SG-2501

N/A

Report date: 2025/03/19 20:00:56

Base Information

Drug NameSG-2501

Drug Alias NameSG-2501

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionLymphocyte differentiation antigen CD38 inhibitorsCluster of differentiation 47 inhibitors

TargetsLymphocyte differentiation antigen CD38Cluster of differentiation 47

Therapy Area/IndicationsHematologic NeoplasmsLymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesHangzhou Shangjian Biotechnology Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesHangzhou Shangjian Biotechnology Co Ltd

Active IndicationsN/A

Inactive IndicationsHematologic NeoplasmsLymphoma

Other Information

ATC CodeN/A